DVAI34 Stock Overview
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
DaVita Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$693.00 |
| 52 Week High | US$731.46 |
| 52 Week Low | US$370.74 |
| Beta | 1.05 |
| 1 Month Change | 4.79% |
| 3 Month Change | n/a |
| 1 Year Change | 57.29% |
| 3 Year Change | 6.29% |
| 5 Year Change | n/a |
| Change since IPO | 245.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| DVAI34 | BR Healthcare | BR Market | |
|---|---|---|---|
| 7D | 0.6% | 0.8% | 0.4% |
| 1Y | 57.3% | 0.9% | 14.6% |
Return vs Industry: DVAI34 exceeded the BR Healthcare industry which returned 0.9% over the past year.
Return vs Market: DVAI34 exceeded the BR Market which returned 14.6% over the past year.
Price Volatility
| DVAI34 volatility | |
|---|---|
| DVAI34 Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 6.8% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in BR Market | 8.9% |
| 10% least volatile stocks in BR Market | 2.2% |
Stable Share Price: DVAI34 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine DVAI34's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 70,000 | Javier Rodriguez | www.davita.com |
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
DaVita Inc. Fundamentals Summary
| DVAI34 fundamental statistics | |
|---|---|
| Market cap | R$63.24b |
| Earnings (TTM) | R$4.13b |
| Revenue (TTM) | R$62.54b |
14.5x
P/E Ratio1.0x
P/S RatioIs DVAI34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DVAI34 income statement (TTM) | |
|---|---|
| Revenue | US$12.34b |
| Cost of Revenue | US$8.35b |
| Gross Profit | US$3.99b |
| Other Expenses | US$3.17b |
| Earnings | US$815.64m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 9.30 |
| Gross Margin | 32.32% |
| Net Profit Margin | 6.61% |
| Debt/Equity Ratio | 346.3% |
How did DVAI34 perform over the long term?
See historical performance and comparison